Related Experiment Video

Updated: Jul 2, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

PAMAM G4 dendrimers lower high glucose but do not improve reduced survival in diabetic rats

Magdalena Labieniec1, Olga Ulicna, Olga Vancova

  • 1Department of General Biophysics, University of Lodz, Lodz, Poland.

International Journal of Pharmaceutics
|September 2, 2008
PubMed

Insights

Poly(amidoamine) dendrimers G4 (PAMAM G4) showed significant cytotoxic effects, increasing mortality in diabetic rats. While PAMAM G4 lowered blood glucose and diabetic markers, its toxicity ultimately proved detrimental.

Area of Science:

  • Biomedical Engineering
  • Toxicology
  • Diabetology

Background:

  • Poly(amidoamine) dendrimers G4 (PAMAM G4) have been recognized for nearly a decade as having significant cytotoxic potential.
  • Severe hyperglycemia is a hallmark of chronic diabetes, posing substantial health risks.

Purpose of the Study:

  • To investigate the in vivo cytotoxic effects of PAMAM G4 in the context of its potential to ameliorate hyperglycemia in streptozotocin-induced diabetic rats.
  • To determine if the glucose-lowering effects of PAMAM G4 could mitigate its inherent cytotoxicity.

Main Methods:

  • Chronic streptozotocin-diabetic Wistar rats were treated with PAMAM G4 (0.5 micromol kg(-1) day(-1)) over a 60-day period.
  • Survival rates and various biochemical parameters in blood, including glucose, glycated hemoglobin, cholesterol, and triglycerides, were monitored.

Main Results:

  • PAMAM G4 significantly reduced overall survival in diabetic rats, with treated animals being 6.7 times more likely to die (p<0.025).
  • PAMAM G4 effectively lowered blood glucose, glycated hemoglobin, protein oxidation, cholesterol, and triglycerides.
  • Terminal blood glucose was higher in survivors, suggesting glycation might offer some protection against PAMAM G4 cytotoxicity.

Conclusions:

  • PAMAM G4 demonstrates in vivo efficacy in reducing plasma glucose and suppressing long-term diabetic hyperglycemia markers.
  • Despite its beneficial metabolic effects, the cytotoxic impact of PAMAM G4 leads to increased mortality in streptozotocin-diabetic rats.
  • The study provides the first in vivo evidence that PAMAM G4's toxicity outweighs its glucose-lowering benefits in this diabetic model.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...